Literature DB >> 17255105

Protein kinase A phosphorylation of human phosphodiesterase 3B promotes 14-3-3 protein binding and inhibits phosphatase-catalyzed inactivation.

Daniel Palmer1, Sandra L Jimmo, Daniel R Raymond, Lindsay S Wilson, Rhonda L Carter, Donald H Maurice.   

Abstract

Recent studies confirm that intracellular cAMP concentrations are nonuniform and that localized subcellular cAMP hydrolysis by cyclic nucleotide phosphodiesterases (PDEs) is important in maintaining these cAMP compartments. Human phosphodiesterase 3B (HSPDE3B), a member of the PDE3 family of PDEs, represents the dominant particulate cAMP-PDE activity in many cell types, including adipocytes and cells of hematopoietic lineage. Although several previous reports have shown that phosphorylation of HSPDE3B by either protein kinase A (PKA) or protein kinase B (PKB) activates this enzyme, the mechanisms that allow cells to distinguish these two activated forms of HSPDE3B are unknown. Here we report that PKA phosphorylates HSPDE3B at several distinct sites (Ser-73, Ser-296, and Ser-318), and we show that phosphorylation of HSPDE3B at Ser-318 activates this PDE and stimulates its interaction with 14-3-3 proteins. In contrast, although PKB-catalyzed phosphorylation of HSPDE3B activates this enzyme, it does not promote 14-3-3 protein binding. Interestingly, we report that the PKA-phosphorylated, 14-3-3 protein-bound, form of HSPDE3B is protected from phosphatase-dependent dephosphorylation and inactivation. In contrast, PKA-phosphorylated HSPDE3B that is not bound to 14-3-3 proteins is readily dephosphorylated and inactivated. Our data are presented in the context that a selective interaction between PKA-activated HSPDE3B and 14-3-3 proteins represents a mechanism by which cells can protect this enzyme from deactivation. Moreover, we propose that this mechanism may allow cells to distinguish between PKA- and PKB-activated HSPDE3B.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17255105     DOI: 10.1074/jbc.M606936200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  20 in total

Review 1.  Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments.

Authors:  Thérèse Keravis; Claire Lugnier
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

2.  Genetic screening for regulators of Prz1, a transcriptional factor acting downstream of calcineurin in fission yeast.

Authors:  Atsushi Koike; Toshiaki Kato; Reiko Sugiura; Yan Ma; Yuki Tabata; Koji Ohmoto; Susie O Sio; Takayoshi Kuno
Journal:  J Biol Chem       Date:  2012-04-11       Impact factor: 5.157

Review 3.  cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action.

Authors:  Sharron H Francis; Jennifer L Busch; Jackie D Corbin; David Sibley
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

Review 4.  Advances in targeting cyclic nucleotide phosphodiesterases.

Authors:  Donald H Maurice; Hengming Ke; Faiyaz Ahmad; Yousheng Wang; Jay Chung; Vincent C Manganiello
Journal:  Nat Rev Drug Discov       Date:  2014-04       Impact factor: 84.694

5.  The Role of PDE3B Phosphorylation in the Inhibition of Lipolysis by Insulin.

Authors:  Lisa M DiPilato; Faiyaz Ahmad; Matthew Harms; Patrick Seale; Vincent Manganiello; Morris J Birnbaum
Journal:  Mol Cell Biol       Date:  2015-06-01       Impact factor: 4.272

6.  Negative regulation of the RalGAP complex by 14-3-3.

Authors:  Dara Leto; Maeran Uhm; Anja Williams; Xiao-wei Chen; Alan R Saltiel
Journal:  J Biol Chem       Date:  2013-02-05       Impact factor: 5.157

7.  Regulation of sarcoplasmic reticulum Ca2+ ATPase 2 (SERCA2) activity by phosphodiesterase 3A (PDE3A) in human myocardium: phosphorylation-dependent interaction of PDE3A1 with SERCA2.

Authors:  Faiyaz Ahmad; Weixing Shen; Fabrice Vandeput; Nicolas Szabo-Fresnais; Judith Krall; Eva Degerman; Frank Goetz; Enno Klussmann; Matthew Movsesian; Vincent Manganiello
Journal:  J Biol Chem       Date:  2015-01-15       Impact factor: 5.157

Review 8.  Regulation of cAMP by phosphodiesterases in erythrocytes.

Authors:  Shaquria P Adderley; Randy S Sprague; Alan H Stephenson; Madelyn S Hanson
Journal:  Pharmacol Rep       Date:  2010 May-Jun       Impact factor: 3.024

Review 9.  Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets.

Authors:  F Ahmad; T Murata; K Shimizu; E Degerman; D Maurice; V Manganiello
Journal:  Oral Dis       Date:  2014-09-12       Impact factor: 3.511

10.  Selective regulation of cyclic nucleotide phosphodiesterase PDE3A isoforms.

Authors:  Fabrice Vandeput; Nicolas Szabo-Fresnais; Faiyaz Ahmad; Changwon Kho; Ahyoung Lee; Judith Krall; Allan Dunlop; Mark W Hazel; James A Wohlschlegel; Roger J Hajjar; Miles D Houslay; Vincent C Manganiello; Matthew A Movsesian
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-18       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.